May 22 2023, IDT-Biologika, a leading Contract Development and Manufacturing Organization (CDMO) specializing in vaccines and gene and immune therapies, has joined the MBC to expand their USA footprint supporting its Rockville MD development and clinical manufacturing facility. A global leader in viral vector manufacturing for multiple clinical and commercial therapeutics in recent years, the company has over 100 years of experience and is headquartered in Dessau-Rosslau Germany. Its end-to-end offer includes process development through drug substance manufacturing up to BSL-2, sterile liquid dosage filling & lyophilization, labeling & packaging to quality control & analytics. The company’s fully integrated services are underscored by its commitment to quality and operational excellence that flows through best-in-class process and cGMP manufacturing capabilities meeting FDA, EMA and ANVISA standards. IDT-Biologika is unique in its ability to accommodate the development, testing and manufacture of products for the world’s leading biopharmaceutical companies. Many human vaccines developed by IDT Biologika, together with international partners, are already in use, fighting infectious diseases such as COVID-19, Tuberculosis, AIDS, Malaria, Dengue Fever, Ebola and Chikungunya.
For more information, please visit our website at:
Home – IDT Biologika (idt-biologika.com)
or follow us on LinkedIn at:
(1) IDT Biologika: Overview | LinkedIn
Latest company brochure attached.